Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

OMNIS, the modular platform for chemical analysis from Metrohm has become ever more powerful. With the launch of the OMNIS ...

This study presents efficient CaO/ZnO composite catalysts for biodiesel production from soybean oil, achieving 99% conversion ...

Raymond James analyst Steven Seedhouse raised the firm’s price target on Viking Therapeutics (VKTX) to $125 from $122 and keeps a Strong Buy ...

Primary aldosteronism treatment response was associated with higher plasma renin activity and serum potassium levels and lower aldosterone.

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

When using high-flow nasal cannula (HFNC), setting a higher flow rate of 60 vs 40 L/min for post-extubation care did not improve key outcomes.